• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $TCRX

    TScan Therapeutics Inc.

    Subscribe to $TCRX
    $TCRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on developing a pipeline of T cell receptor-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, and TSC-203 for the treatment of solid tumors. The company has a collaboration and license agreement with Novartis Institutes for Biomedical Research, Inc. to discover and develop novel TCR-T therapies. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

    IPO Year: 2021

    Exchange: NASDAQ

    Website: tscan.com

    Recent Analyst Ratings for TScan Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    5/16/2024$12.00Buy
    BTIG Research
    5/13/2024$11.00Buy
    Needham
    6/22/2023$8.00Outperform
    Wedbush
    12/16/2021$21.00Buy
    HC Wainwright & Co.
    8/13/2021Outperform
    Cowen & Co.
    8/10/2021$22.00Overweight
    Barclays
    8/10/2021$22.00Overweight
    Morgan Stanley
    8/10/2021$21.00Buy
    Jefferies
    See more ratings

    TScan Therapeutics Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by TScan Therapeutics Inc.

      10-Q - TScan Therapeutics, Inc. (0001783328) (Filer)

      5/6/25 7:30:20 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - TScan Therapeutics, Inc. (0001783328) (Filer)

      5/6/25 7:15:10 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by TScan Therapeutics Inc.

      EFFECT - TScan Therapeutics, Inc. (0001783328) (Filer)

      3/17/25 12:15:08 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by TScan Therapeutics Inc.

      S-8 - TScan Therapeutics, Inc. (0001783328) (Filer)

      3/5/25 4:28:14 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-3 filed by TScan Therapeutics Inc.

      S-3 - TScan Therapeutics, Inc. (0001783328) (Filer)

      3/5/25 4:25:44 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by TScan Therapeutics Inc.

      10-K - TScan Therapeutics, Inc. (0001783328) (Filer)

      3/5/25 7:30:50 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - TScan Therapeutics, Inc. (0001783328) (Filer)

      3/5/25 7:15:08 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by TScan Therapeutics Inc.

      SCHEDULE 13G/A - TScan Therapeutics, Inc. (0001783328) (Subject)

      2/14/25 9:00:17 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by TScan Therapeutics Inc.

      SCHEDULE 13G/A - TScan Therapeutics, Inc. (0001783328) (Subject)

      2/12/25 9:38:24 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by TScan Therapeutics Inc.

      8-K - TScan Therapeutics, Inc. (0001783328) (Filer)

      12/26/24 7:30:30 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    TScan Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Updates from the PLEXI-T™ solid tumor and ALLOHA™ heme Phase 1 clinical trials anticipated by end of year On-track to file IND application for TSC-102-A0301 (CD45; HLA-A*03:01) to FDA in the second half of the year Appointed commercial leader Stephen Camiolo as Senior Vice President, Market Access Cash, cash equivalents, and marketable securities continue to fund operations into the first quarter of 2027 WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported fina

      5/6/25 7:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

      WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of an abstract for poster presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28ᵗʰ Annual Meeting being held May 13 – 17 in New Orleans, LA as well as virtually. Poster Presentation Details: Title: CD45 as a Universal Target for Adjuvant TCR-T Cell Therapy Following Allogeneic Hematopoietic Cell TransplantationAuthors: Kostadin O Petrov, Stephen P Carroll, Kenneth L Jahan, R

      4/28/25 4:53:52 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

      WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 9:30 a.m. Eastern Time. A webcast of the fireside chat will be available on the "Events and Presentations" section of the Company's website at ir.tscan.com. An archived replay of the webcast will be available on the Company's website for 90 days following the event. About TScan Th

      3/31/25 7:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

      WALTHAM, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the appointment of Stephen Camiolo as Senior Vice President, Market Access. Mr. Camiolo brings to TScan over 25 years of experience in market access, reimbursement, pricing strategy, sales, marketing, and account management across the pharmaceutical and biotechnology industries. "We are delighted to welcome Stephen to TScan at this stage of growth for the Company," said Gavin MacBeath, Ph.D., Chief Executive Officer.

      3/27/25 7:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Presented updated data from ongoing ALLOHA™ Phase 1 heme trial at the 66th ASH Annual Meeting and Exposition IND application cleared for seventh TCR in PLEXI-T™ Phase 1 solid tumor program; TSC-202-A0201 targeting MAGE-A4 on HLA-A*02:01 Closed $30 million registered direct offering at 37% premium with long-standing, supportive shareholder Cash, cash equivalents, and marketable securities continue to fund operations into the first quarter of 2027 WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patie

      3/5/25 7:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference

      WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will present at the TD Cowen 45th Annual Health Care Conference being held at the Marriott Copley Place in Boston, MA on Wednesday, March 5, 2025 at 1:10 p.m. Eastern Time. A webcast of the presentation will be available on the "Events and Presentations" section of the Company's website at ir.tscan.com. An archived replay of the webcast will be available on the Company's website for 90 days following

      2/27/25 7:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

      WALTHAM, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on Tuesday, February 25, 2025 at 10:00 a.m. Eastern Time. A webcast of the fireside chat will be available on the "Events and Presentations" section of the Company's website at ir.tscan.com. An archived replay of the webcast will be available on the Company's website for 90 days following the event.

      2/18/25 7:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

      WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that it has entered into a securities purchase agreement with Lynx1 Capital Management LP (Lynx1) and an investment fund advised by Lynx1 for the sale of approximately $30 million of pre-funded warrants to purchase up to an aggregate of 7,500,000 shares of its voting common stock at a price of $4.00 per pre-funded warrant, each exercisable to purchase one share of voting common stock at an exercise price of $0.0001 per

      12/26/24 7:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank

      WALTHAM, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that it has entered into a term loan facility with Silicon Valley Bank (SVB), a division of First Citizens Bank, for up to $52.5 million. The first tranche of $32.5 million, advanced at loan closing, will be used to retire the existing convertible debt with K2 Health Ventures and the remainder for general corporate purposes. TScan has the option through June 30, 2026, to draw the second $20.0 million tranche, subj

      12/23/24 7:00:00 AM ET
      $FCNCA
      $TCRX
      Major Banks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition

      To date, event-free survival strongly favors the treatment arm (HR=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse (HR=0.28; p=0.14) No dose-limiting toxicities observed and infusions of TSC-100 and TSC-101 were well-tolerated across all three dose levels Company to host virtual KOL event featuring Ran Reshef, M.D., M.Sc., on Tuesday, December 10, 2024, at 8:00 a.m. ET WALTHAM, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that upd

      12/9/24 5:45:00 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    TScan Therapeutics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    TScan Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    TScan Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Lynx1 Capital Management Lp bought $95,629 worth of shares (31,800 units at $3.01) and bought $290,140 worth of shares (100,000 units at $2.90) (SEC Form 4)

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      12/16/24 4:26:18 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Lynx1 Capital Management Lp bought $4,114 worth of shares (947 units at $4.34) (SEC Form 4)

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      11/19/24 4:26:43 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Klencke Barbara bought $26,450 worth of Voting Common Stock (5,000 units at $5.29), increasing direct ownership by 12% to 45,000 units (SEC Form 4)

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      9/24/24 5:26:24 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Klencke Barbara bought $56,100 worth of Voting Common Stock (10,000 units at $5.61), increasing direct ownership by 33% to 40,000 units (SEC Form 4)

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      8/27/24 6:57:46 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Barberich Timothy J bought $142,456 worth of Voting Common Stock (29,147 units at $4.89), increasing direct ownership by 77% to 67,027 units (SEC Form 4)

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      12/21/23 5:00:47 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Klencke Barbara bought $25,400 worth of Voting Common Stock (5,000 units at $5.08), increasing direct ownership by 20% to 30,000 units (SEC Form 4)

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      12/18/23 6:01:18 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BTIG Research initiated coverage on TScan Therapeutics with a new price target

      BTIG Research initiated coverage of TScan Therapeutics with a rating of Buy and set a new price target of $12.00

      5/16/24 7:35:53 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Needham initiated coverage on TScan Therapeutics with a new price target

      Needham initiated coverage of TScan Therapeutics with a rating of Buy and set a new price target of $11.00

      5/13/24 8:33:06 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wedbush initiated coverage on TScan Therapeutics with a new price target

      Wedbush initiated coverage of TScan Therapeutics with a rating of Outperform and set a new price target of $8.00

      6/22/23 7:30:31 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. initiated coverage on TScan Therapeutics with a new price target

      HC Wainwright & Co. initiated coverage of TScan Therapeutics with a rating of Buy and set a new price target of $21.00

      12/16/21 6:13:35 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cowen & Co. initiated coverage on TScan Therapeutics

      Cowen & Co. initiated coverage of TScan Therapeutics with a rating of Outperform

      8/13/21 5:58:26 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Barclays initiated coverage on TScan Therapeutics with a new price target

      Barclays initiated coverage of TScan Therapeutics with a rating of Overweight and set a new price target of $22.00

      8/10/21 7:07:11 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Morgan Stanley initiated coverage on TScan Therapeutics with a new price target

      Morgan Stanley initiated coverage of TScan Therapeutics with a rating of Overweight and set a new price target of $22.00

      8/10/21 6:03:27 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jefferies initiated coverage on TScan Therapeutics with a new price target

      Jefferies initiated coverage of TScan Therapeutics with a rating of Buy and set a new price target of $21.00

      8/10/21 5:32:48 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Vice President, Finance Dworak Leiden

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      2/11/25 5:54:39 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Officer Zdraveski Zoran

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      2/11/25 5:54:41 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Macbeath Gavin

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      2/11/25 5:52:57 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Amello Jason

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      2/11/25 5:47:29 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Louis Chrystal

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      2/11/25 5:47:00 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Large owner Lynx1 Capital Management Lp

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      12/30/24 4:15:18 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Lynx1 Capital Management Lp bought $95,629 worth of shares (31,800 units at $3.01) and bought $290,140 worth of shares (100,000 units at $2.90) (SEC Form 4)

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      12/16/24 4:26:18 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Lynx1 Capital Management Lp bought $4,114 worth of shares (947 units at $4.34) (SEC Form 4)

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      11/19/24 4:26:43 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Klencke Barbara bought $26,450 worth of Voting Common Stock (5,000 units at $5.29), increasing direct ownership by 12% to 45,000 units (SEC Form 4)

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      9/24/24 5:26:24 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Klencke Barbara bought $56,100 worth of Voting Common Stock (10,000 units at $5.61), increasing direct ownership by 33% to 40,000 units (SEC Form 4)

      4 - TScan Therapeutics, Inc. (0001783328) (Issuer)

      8/27/24 6:57:46 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    TScan Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by TScan Therapeutics Inc.

      SC 13G/A - TScan Therapeutics, Inc. (0001783328) (Subject)

      11/14/24 4:40:11 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by TScan Therapeutics Inc.

      SC 13G/A - TScan Therapeutics, Inc. (0001783328) (Subject)

      11/14/24 4:05:31 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by TScan Therapeutics Inc.

      SC 13G/A - TScan Therapeutics, Inc. (0001783328) (Subject)

      11/14/24 3:05:59 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by TScan Therapeutics Inc.

      SC 13G - TScan Therapeutics, Inc. (0001783328) (Subject)

      4/29/24 4:02:13 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by TScan Therapeutics Inc. (Amendment)

      SC 13D/A - TScan Therapeutics, Inc. (0001783328) (Subject)

      4/23/24 4:25:52 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by TScan Therapeutics Inc. (Amendment)

      SC 13G/A - TScan Therapeutics, Inc. (0001783328) (Subject)

      2/14/24 4:45:41 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by TScan Therapeutics Inc. (Amendment)

      SC 13G/A - TScan Therapeutics, Inc. (0001783328) (Subject)

      2/9/24 4:08:06 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by TScan Therapeutics Inc. (Amendment)

      SC 13G/A - TScan Therapeutics, Inc. (0001783328) (Subject)

      2/8/24 6:02:46 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by TScan Therapeutics Inc. (Amendment)

      SC 13G/A - TScan Therapeutics, Inc. (0001783328) (Subject)

      2/7/24 7:45:25 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by TScan Therapeutics Inc.

      SC 13G - TScan Therapeutics, Inc. (0001783328) (Subject)

      6/12/23 4:30:19 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    TScan Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

      All eight (100%) treatment-arm patients are relapse-free and have achieved and maintained complete donor chimerism following treatment with TSC-100 or TSC-101 Patient with high-risk, TP53-mutated MDS is relapse-free for over one year following treatment with TSC-101 Patient with AML converted from detectable to undetectable disease following treatment with TSC-101 Data presented at TANDEM meeting suggests complete donor chimerism is an early indicator of treatment success Company to host virtual KOL event today, Monday, February 26, at 8:00 a.m. ET, to discuss the data presented at the 2024 Tandem Meetings WALTHAM, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) --  TScan Th

      2/26/24 7:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AMGEN AND TSCAN THERAPEUTICS ANNOUNCE COLLABORATION TO IDENTIFY NOVEL TARGETS IN CROHN'S DISEASE

      Collaboration Brings Together TScan's Proprietary Target Discovery Platform and Amgen's Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million THOUSAND OAKS, Calif. and WALTHAM, Mass., May 9, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and TScan Therapeutics, Inc. (NASDAQ:TCRX), today announced a multi-year collaboration that will use TScan's proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn's disease. Under the terms of the agreement, TScan will receive a $30 million upfront payment and is eligible t

      5/9/23 9:00:00 AM ET
      $AMGN
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn's Disease

      Collaboration Brings Together TScan's Proprietary Target Discovery Platform and Amgen's Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million THOUSAND OAKS, Calif. and WALTHAM, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Amgen (NASDAQ:AMGN) and TScan Therapeutics, Inc. (NASDAQ:TCRX), today announced a multi-year collaboration that will use TScan's proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn's disease. Under the terms of the agreement, TScan will receive a $30 million upfront payment and i

      5/9/23 9:00:00 AM ET
      $AMGN
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress

      Phase 1 umbrella trial for hematologic malignancies open for enrollment Publication in Cell further validates use of foundational technology to identify novel tumor antigens and effective TCRs TSC-200-A2 (HPV) and TSC-204-C7 (MAGE-A1) IND filings anticipated by year-end 2022 Appointment of Debora Barton, M.D., as Chief Medical Officer Ended quarter with cash and cash equivalents of $125.6 million, funding operations into 2024 WALTHAM, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer,

      8/10/22 7:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    TScan Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

      WALTHAM, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the appointment of Stephen Camiolo as Senior Vice President, Market Access. Mr. Camiolo brings to TScan over 25 years of experience in market access, reimbursement, pricing strategy, sales, marketing, and account management across the pharmaceutical and biotechnology industries. "We are delighted to welcome Stephen to TScan at this stage of growth for the Company," said Gavin MacBeath, Ph.D., Chief Executive Officer.

      3/27/25 7:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

      FDA grants RMAT designation to TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning Engaged CDMO with global capabilities to support manufacturing for pivotal trials and commercialization On-track to report initial data from the solid tumor program and one-year data on initial patients in the ALLOHATM Phase 1 heme trial by the end of 2024 Cash, cash equivalents, and marketable securities continue to fund operations into the fourth quarter of 2026 WALTHAM, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T

      8/12/24 7:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer

      WALTHAM, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer. Dr. Louis has extensive experience in hematology and oncology drug development, with a track record of success in clinical development, medical affairs, and commercialization. "We are excited to welcome Chrystal to TScan at this critical time as we continue to progress both clinical-stage programs in heme malignancies and solid tumors

      4/8/24 8:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development

      WALTHAM, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development. Dr. Pinchasik brings to TScan over a decade of experience in clinical development across the pharmaceutical and biotechnology industry. "We are pleased to welcome Dawn to TScan at such an exciting time in the Company's evolution," said Debora Barton, M.D., Chief Medical Officer. "Her expertise in cell and gene therapy clinical

      2/6/24 7:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer

      WALTHAM, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of Jason A. Amello as Chief Financial Officer. Mr. Amello, a senior finance executive, brings to TScan nearly three decades of expertise in financial strategy, business development, and operations in the biotechnology industry. "We are pleased to welcome Jason to TScan at such an exciting time as we continue to make significant progress across both our heme and solid tumor programs, with multiple i

      1/29/24 7:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations

      WALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of R. Keith Woods to its Board of Directors. Mr. Woods has over 30 years of life science experience, with expertise in commercialization, sales, global operations, supply chain and business strategy. "I am pleased to welcome Keith, a highly respected and experienced leader in biotechnology, as our newest member to the Board of Directors," said Gavin MacBeath, Ph.D., Chief Executive Officer. "In his

      12/7/23 7:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology Officer

      WALTHAM, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of Justin McCue, Ph.D., as its Chief Technology Officer. Dr. McCue joins TScan with over 20 years of experience in biologics and cell therapy manufacturing, including process/analytical development, technical operations, clinical development, and commercialization of T cell therapy products. "We are delighted to welcome Justin to TScan. His extensive expertise is a valuable addition to the Compan

      12/4/23 7:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors

      BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sensorium Therapeutics (Sensorium), a biotechnology company translating insights from nature and human experience to deliver transformational therapeutics, today announced the appointment of veteran life sciences executive David Southwell to its Board of Directors. "We are excited to welcome David to our Board," said Dick Simon, Chief Executive Officer of Sensorium. "He is a seasoned life sciences executive with a track record of success that spans multiple therapeutic areas and development stages. David's depth of experience will be a key asset as we advance our lead program, SENS-01, towards the clinic and expand our drug pipeline into addition

      9/12/23 8:00:00 AM ET
      $PTCT
      $SPRO
      $TCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors

      WALTHAM, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX) (TScan), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that its Board of Directors (the Board) has appointed Gavin MacBeath, Ph.D., as Chief Executive Officer (CEO) of TScan and as a Class I Director of its Board, each effective as of May 24, 2023. Dr. MacBeath, has been serving as acting CEO since March 2023. Dr. MacBeath will no longer serve as Chief Scientific and Operating Officer of the Company, effective May 24, 2023. Dr. MacBeath joined TScan in 2018 and

      5/24/23 4:13:47 PM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

      Entered into partnership with Amgen to identify novel targets in Crohn's disease; TScan to receive $30 million upfront Enrolled patients in all three arms of Phase 1 hematologic malignancies study; TSC-101 progressing to second dose level Announced upcoming trial-in-progress poster presentation on 5/17 at ASGCT, followed by call at 5:30 p.m. ET Appointed Barbara Klencke, M.D., to Board of Directors Ended 1Q 2023 with cash and cash equivalents of $95.6 million, which combined with Amgen partnership extends cash runway into 3Q 2024 WALTHAM, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX) ("TScan" or the "Company"), a clinical-stage biopharmaceutical compa

      5/10/23 7:00:00 AM ET
      $TCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care